Gamida Cell Stock Return On Equity

GMDADelisted Stock  USD 1.40  0.09  6.04%   
Gamida Cell fundamentals help investors to digest information that contributes to Gamida Cell's financial success or failures. It also enables traders to predict the movement of Gamida Stock. The fundamental analysis module provides a way to measure Gamida Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gamida Cell stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gamida Cell Company Return On Equity Analysis

Gamida Cell's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Gamida Cell Return On Equity

    
  -11.04  
Most of Gamida Cell's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gamida Cell is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Gamida Cell has a Return On Equity of -11.0379. This is 53.95% lower than that of the Biotechnology sector and 69.73% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Gamida Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gamida Cell's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gamida Cell could also be used in its relative valuation, which is a method of valuing Gamida Cell by comparing valuation metrics of similar companies.
Gamida Cell is currently under evaluation in return on equity category among its peers.

Gamida Fundamentals

About Gamida Cell Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Gamida Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gamida Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gamida Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Gamida Stock

If you are still planning to invest in Gamida Cell check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gamida Cell's history and understand the potential risks before investing.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years